ArticleBioinformation2025
Gene expression analysis of epithelial-mesenchymal transition markers in oral submucous fibrosis fibroblasts treated with arecoline.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSF), a potentially malignant disorder, is strongly linked to areca nut consumption, with arecoline inducing epithelial-mesenchymal transition (EMT) in fibroblasts. Therfeore, it is of interest to investigate EMT marker expression in OSF fibroblasts exposed to arecoline and assessed the inhibitory effects of curcumin and epigallocatechin-3-gallate (EGCG). Primary fibroblasts from OSF and normal mucosa were treated and EMT markers were analyzed by RT-qPCR, Western blotting and wound healing assays. Arecoline decreased E-cadherin and increased N-cadherin, vimentin, α-SMA, Snail, Twist and migration rate, whereas co-treatment with curcumin or EGCG significantly reversed these effects, with curcumin showing greater efficacy. Thus, we show that curcumin and EGCG inhibit arecoline-induced EMT and may serve as potential therapeutic agents in OSF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.